While further research is needed, these results are a great start as they offer hope to the approximately 250,000 people worldwide struggling with this devastating condition.
MGC Pharmaceuticals , a publicly-traded cannabis company, recently finalized pre-clinical trial research of cannabinoids as a potential treatment for glioblastoma, an aggressive brain cancer. The results were positive, reported CityA.M.
The European-based bio-pharma company specializing in the production and development of phytomedicines said that the three-year in-vitro trial delivered “outstanding results.”
– Read the entire article at The Fresh Toast.
